# Clinical Trials Data EGFR - Document 44

# Combined Treatment of Cetuximab and Paclitaxel in Basal Like Breast Carcinoma

## Clinical Trial: https://clinicaltrials.gov/study/NCT00353717

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Patients with metastatic breast carcinoma of the basal like subtype with available biopsy for analysis and ECOG PS of 2 or less\n\nExclusion Criteria:\n\n\* Pregnancy\n\* BUN, blood creatinine, AST, ALT \\> X3 of upper limits of normal\n\* More than previous 2 chemotherapy lines in the metastatic settings or the use of previous inhibitors of EGFR",  
 "healthyVolunteers": false,  
 "sex": "FEMALE",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided eligibility criteria for the clinical trial, a patient with an EGFR gene mutation would not be excluded based solely on the presence of this mutation. The exclusion criteria specifically mention a history of using previous inhibitors of EGFR as a factor for exclusion, not the mutation itself. Thus, if the patient has not used EGFR inhibitors previously, their mutation status would not make them ineligible.  
  
To determine full eligibility, ensure the patient also meets the other inclusion criteria (such as having metastatic breast carcinoma of the basal-like subtype and an ECOG performance status of 2 or less) and does not meet any other exclusion criteria listed.